Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Jun;35(6):1017-22.

Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49

R F Meredith  1 , A J Bueschen, M B Khazaeli, W E Plott, W E Grizzle, R H Wheeler, J Schlom, C D Russell, T Liu, A F LoBuglio
Affiliations
  • PMID: 8195861
Free article
Clinical Trial

Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49

R F Meredith et al. J Nucl Med. 1994 Jun.
Free article

Abstract

A Phase II trial of 75 mCi/m2 131I-anti-TAG-72 high-affinity antibody CC49 was studied in 15 patients with hormone-resistant metastatic prostate cancer.

Methods: Patients had adequate renal, liver and hematopoietic function. No previous cytotoxic chemotherapy was allowed and previous radiation was limited to 20% of the active bone marrow.

Results: No acute adverse reactions occurred, but all patients had evidence of an immune response to CC49 by 4 wk. Six of 10 symptomatic patients had bone pain relief, but no patients met the radiographic or PSA criteria for objective response. Positive imaging of bone and/or soft-tissue lesions was noted for 13 of the 15 patients.

Conclusions: CC49 had a high frequency of tumor localization with evidence of anti-tumor effects (pain relief).

PubMed Disclaimer

Publication types

LinkOut - more resources